2009
Pharmacotherapeutic Effects of Opioid Antagonists in Alcohol-Abusing Patients with Schizophrenia
Petrakis I. Pharmacotherapeutic Effects of Opioid Antagonists in Alcohol-Abusing Patients with Schizophrenia. Contemporary Neuroscience 2009, 473-483. DOI: 10.1007/978-1-59745-197-0_25.Peer-Reviewed Original ResearchAlcohol use disorderOpioid antagonist naltrexoneUse disordersAntagonist naltrexoneTherapeutic optionsGeneral populationSchizoaffective disorderDevastating clinical disorderOpioid antagonist treatmentBest therapeutic optionGroup of patientsUse of naltrexoneSymptoms of psychosisNoncomorbid patientsPharmacologic managementAntagonist treatmentOpioid antagonistAlcohol use/dependenceComorbid schizophreniaClinical trialsPharmacotherapeutic effectsSchizophrenic patientsPatientsSide effectsCognitive symptoms
2005
Mazindol Augmentation of Antipsychotic Treatment for Schizophrenic Patients with Comorbid Cocaine Abuse or Dependence
Perry E, Gil R, Miles D, Brenner L, Macdougall L, Johnson R, Degen K, Gueorguieva R, Petrakis I, Krystal J, D'Souza D. Mazindol Augmentation of Antipsychotic Treatment for Schizophrenic Patients with Comorbid Cocaine Abuse or Dependence. Journal Of Dual Diagnosis 2005, 1: 37-47. DOI: 10.1300/j374v01n01_04.Peer-Reviewed Original ResearchCocaine abusePsychiatric symptomsCocaine cravingCatecholamine reuptake inhibitorCurrent antipsychotic medicationsCocaine consumptionPlacebo groupAntipsychotic pharmacotherapyReuptake inhibitorsAntipsychotic medicationAntipsychotic treatmentComorbid schizophreniaSchizoaffective patientsSubstance abuse issuesSchizophrenic patientsPatientsSchizoaffective disorderSchizophrenia patientsNatural historyMazindolPilot studyGroup therapySchizophreniaSymptomsAbuse issues
1999
Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients
Krystal J, D'Souza D, Madonick S, Petrakis I. Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophrenia Research 1999, 35: s35-s49. PMID: 10190224, DOI: 10.1016/s0920-9964(98)00162-5.Peer-Reviewed Original ResearchConceptsSchizophrenic patientsSubstance abuseTerms of rehospitalizationComorbid substance abuseExacerbation of symptomsHealth care expensesSelf-medication hypothesisBetter prognosisMedical illnessPharmacotherapeutic approachesRational pharmacotherapyNonschizophrenic populationsPatientsVocational functionIllicit substancesCare expensesAbuseVulnerability hypothesisRehospitalizationExacerbationMedicationsPharmacotherapyPrognosisPsychostimulantsIllness
1992
Adjunctive desipramine in the treatment of cocaine abusing schizophrenics.
Ziedonis D, Richardson T, Lee E, Petrakis I, Kosten T. Adjunctive desipramine in the treatment of cocaine abusing schizophrenics. Psychopharmacology Bulletin 1992, 28: 309-14. PMID: 1480735.Peer-Reviewed Original ResearchConceptsAntipsychotic agentsSchizophrenic patientsOpen-label outpatient studySubstance abuse relapse preventionTreatment programDual diagnosis treatment programOnly antipsychotic agentTreatment of cocaineCocaine-positive urinesLifetime prevalence ratesRelapse prevention programAdjunctive pharmacotherapyOutpatient studyPrevalence ratesPsychiatric symptomsPatientsCocaine abuseRelapse preventionPrevention programsCocaine usageDMI groupPharmacotherapyDesipramineSymptomsAgents